Poniard Pharmaceuticals, Inc. (PARD)

Market Cap	150.00 -99.9%
Revenue (ttm)	n/a
Net Income	-16.23M
EPS	-3.79
Shares Out	1.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	n/a
Beta	-60.04
Analysts	n/a
Price Target	40.00 (+39,999,900.0%)
Earnings Date	n/a

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1984
• Employees: 8
• Stock Exchange: OTCMKTS
• Ticker Symbol: PARD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error